Integrated Quantitative Investments LLC Cuts Position in Phibro Animal Health Corporation $PAHC

Integrated Quantitative Investments LLC trimmed its position in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 33.5% during the 3rd quarter, Holdings Channel reports. The fund owned 32,470 shares of the company’s stock after selling 16,361 shares during the period. Integrated Quantitative Investments LLC’s holdings in Phibro Animal Health were worth $1,314,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. EverSource Wealth Advisors LLC increased its position in Phibro Animal Health by 7,671.4% in the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after purchasing an additional 2,685 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Phibro Animal Health by 768.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock worth $118,000 after buying an additional 4,079 shares during the last quarter. State of Wyoming boosted its stake in Phibro Animal Health by 148.8% during the second quarter. State of Wyoming now owns 6,608 shares of the company’s stock worth $169,000 after buying an additional 3,952 shares during the period. Cornerstone Investment Partners LLC bought a new position in Phibro Animal Health in the 3rd quarter valued at $209,000. Finally, Balboa Wealth Partners bought a new stake in shares of Phibro Animal Health during the third quarter worth $216,000. 99.34% of the stock is owned by hedge funds and other institutional investors.

Phibro Animal Health Trading Down 0.7%

Shares of NASDAQ:PAHC opened at $51.89 on Thursday. Phibro Animal Health Corporation has a 1 year low of $16.16 and a 1 year high of $56.30. The firm has a market capitalization of $2.10 billion, a P/E ratio of 23.06, a P/E/G ratio of 0.80 and a beta of 0.74. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22. The business’s 50-day moving average is $44.68 and its 200 day moving average is $41.39.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.18. The firm had revenue of $373.91 million for the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, research analysts predict that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th will be paid a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Wednesday, March 4th. Phibro Animal Health’s payout ratio is 21.33%.

Insider Transactions at Phibro Animal Health

In other news, CEO Jack Bendheim sold 7,040 shares of the firm’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $53.73, for a total value of $378,259.20. Following the transaction, the chief executive officer directly owned 1,480 shares of the company’s stock, valued at approximately $79,520.40. This trade represents a 82.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Over the last 90 days, insiders have sold 299,200 shares of company stock worth $14,249,723. Insiders own 50.13% of the company’s stock.

Analyst Upgrades and Downgrades

PAHC has been the topic of a number of research analyst reports. Zacks Research cut shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a research report on Friday, February 6th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Finally, JPMorgan Chase & Co. raised their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $37.50.

Phibro Animal Health Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.